% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rhle:271248,
      author       = {A. Rühle$^*$ and S. Marschner$^*$ and M. Haderlein and A.
                      Fabian and M. Weymann and M. Behrens and C. Senger$^*$ and
                      D. R. Dickstein and J. Kraft and J. von der Grün$^*$ and E.
                      Chen and T. Aquino-Michaels and J. Domschikowski and A.
                      Bickel and A. Altay-Langguth$^*$ and G. Kalinauskaite$^*$
                      and V. Lewitzki and K. Ferentinos and C. Zamboglou$^*$ and
                      S. Schnellhardt and E. Haehl$^*$ and S. K. B. Spohn$^*$ and
                      E. Gkika$^*$ and D. Zöller and M. Guckenberger and V.
                      Budach$^*$ and C. Belka$^*$ and R. Bakst and A. Mayer$^*$
                      and H. Schmidberger$^*$ and A.-L. Grosu$^*$ and P. Balermpas
                      and C. Stromberger$^*$ and N. Nicolay$^*$},
      title        = {{E}valuation of {C}oncomitant {S}ystemic {T}reatment in
                      {O}lder {A}dults {W}ith {H}ead and {N}eck {S}quamous {C}ell
                      {C}arcinoma {U}ndergoing {D}efinitive {R}adiotherapy.},
      journal      = {JAMA network open},
      volume       = {6},
      number       = {2},
      issn         = {2574-3805},
      address      = {Chicago, Ill.},
      publisher    = {American Medical Association},
      reportid     = {DKFZ-2023-00380},
      pages        = {e230090},
      year         = {2023},
      abstract     = {The number of older adults with head and neck squamous cell
                      carcinoma (HNSCC) is increasing, and these patients are
                      underrepresented in clinical trials. It is unclear whether
                      the addition of chemotherapy or cetuximab to radiotherapy is
                      associated with improved survival in older adults with
                      HNSCC.To examine whether the addition of chemotherapy or
                      cetuximab to definitive radiotherapy is associated with
                      improved survival in patients with locoregionally advanced
                      (LA) HNSCC.The Special Care Patterns for Elderly HNSCC
                      Patients Undergoing Radiotherapy (SENIOR) study is an
                      international, multicenter cohort study including older
                      adults (≥65 years) with LA-HNSCCs of the oral cavity,
                      oropharynx/hypopharynx, or larynx treated with definitive
                      radiotherapy, either alone or with concomitant systemic
                      treatment, between January 2005 and December 2019 at 12
                      academic centers in the US and Europe. Data analysis was
                      conducted from June 4 to August 10, 2022.All patients
                      underwent definitive radiotherapy alone or with concomitant
                      systemic treatment.The primary outcome was overall survival.
                      Secondary outcomes included progression-free survival and
                      locoregional failure rate.Among the 1044 patients (734 men
                      $[70.3\%];$ median [IQR] age, 73 [69-78] years) included in
                      this study, 234 patients $(22.4\%)$ were treated with
                      radiotherapy alone and 810 patients $(77.6\%)$ received
                      concomitant systemic treatment with chemotherapy (677
                      $[64.8\%])$ or cetuximab (133 $[12.7\%]).$ Using inverse
                      probability weighting to attribute for selection bias,
                      chemoradiation was associated with longer overall survival
                      than radiotherapy alone (hazard ratio [HR], 0.61; $95\%$ CI,
                      0.48-0.77; P < .001), whereas cetuximab-based
                      bioradiotherapy was not (HR, 0.94; $95\%$ CI, 0.70-1.27; P =
                      .70). Progression-free survival was also longer after the
                      addition of chemotherapy (HR, 0.65; $95\%$ CI, 0.52-0.81; P
                      < .001), while the locoregional failure rate was not
                      significantly different (subhazard ratio, 0.62; $95\%$ CI,
                      0.30-1.26; P = .19). The survival benefit of the
                      chemoradiation group was present in patients up to age 80
                      years (65-69 years: HR, 0.52; $95\%$ CI, 0.33-0.82; 70-79
                      years: HR, 0.60; $95\%$ CI, 0.43-0.85), but was absent in
                      patients aged 80 years or older (HR, 0.89; $95\%$ CI,
                      0.56-1.41).In this cohort study of older adults with LA-
                      HNSCC, chemoradiation, but not cetuximab-based
                      bioradiotherapy, was associated with longer survival
                      compared with radiotherapy alone.},
      cin          = {FR01 / MU01 / BE01 / FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331 / I:(DE-He78)MU01-20160331 /
                      I:(DE-He78)BE01-20160331 / I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36808242},
      doi          = {10.1001/jamanetworkopen.2023.0090},
      url          = {https://inrepo02.dkfz.de/record/271248},
}